(Q57924698)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Treatment of behavioral and psychological symptoms of Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Byron Creese

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Clive Ballard

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Jessica Smith

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

Current treatment options in neurology

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

113-125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11940-012-0166-9

22 January 2020

exact match

0 references

cites work

Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Hallucinations and associated factors in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

A follow up study of depression in the carers of dementia sufferers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Management of verbally disruptive behaviors in nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Neuroleptic drugs in dementia: benefits and harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Donepezil for the treatment of agitation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

21 January 2018

12 December 2020

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0166-9

Neuroleptic Drugs in the Management of Behavioral Symptoms of Alzheimer’s Disease

21 January 2018

1 reference

12 December 2020

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

1 reference

12 December 2020

Correlates of psychotic symptoms among elderly outpatients

1 reference

12 December 2020

Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments

1 reference

12 December 2020

Delusions associated with elevated muscarinic binding in dementia with Lewy bodies.

1 reference

12 December 2020

The impact of dementia on the family

1 reference

12 December 2020

Management of agitation and aggression associated with Alzheimer disease

1 reference

12 December 2020

A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease

1 reference

12 December 2020

Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older

1 reference

12 December 2020

Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies

1 reference

12 December 2020

Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease: treatment implications.

1 reference

12 December 2020

Memantine for dementia

1 reference

12 December 2020

A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia

1 reference

12 December 2020

The utility of pain assessment for analgesic use in persons with dementia

1 reference

12 December 2020

10.1007/S11940-012-0166-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328204%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference